Irinotecan liposomal (Runshi Pharmaceutical)

伊立替康脂质体 (润石医药科技)

Report date: 2025/05/26 20:01:03

Base Information

Drug NameIrinotecan liposomal (Runshi Pharmaceutical)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsStomach NeoplasmsEsophageal Squamous Cell Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShanghai Runshi Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShanghai Runshi Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsStomach NeoplasmsEsophageal Squamous Cell Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A